JPH0568449B2 - - Google Patents

Info

Publication number: JPH0568449B2
Authority: JP; Japan
Prior art keywords: composition; weight; urine; potassium chloride; sodium citrate
Prior art date: 1984-03-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP59055159A

Other languages

English (en)

Japanese (ja)

Other versions

JPS60197623A (ja

Inventor

Shigeki Shin

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Nippon Chemiphar Co Ltd

Original Assignee

Nippon Chemiphar Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-03-21

Filing date

1984-03-21

Publication date

1993-09-29

1984-03-21 Application filed by Nippon Chemiphar Co Ltd filed Critical Nippon Chemiphar Co Ltd

1984-03-21 Priority to JP5515984A priority Critical patent/JPS60197623A/ja

1985-10-07 Publication of JPS60197623A publication Critical patent/JPS60197623A/ja

1993-09-29 Publication of JPH0568449B2 publication Critical patent/JPH0568449B2/ja

Status Granted legal-status Critical Current

Links

KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 77
239000000203 mixture Substances 0.000 claims description 77
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 54
210000002700 urine Anatomy 0.000 claims description 35
239000001103 potassium chloride Substances 0.000 claims description 26
235000011164 potassium chloride Nutrition 0.000 claims description 26
239000001509 sodium citrate Substances 0.000 claims description 26
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 25
230000003113 alkalizing effect Effects 0.000 claims description 12
239000003795 chemical substances by application Substances 0.000 claims description 11
150000001720 carbohydrates Chemical class 0.000 claims 1
235000015165 citric acid Nutrition 0.000 description 25
235000011083 sodium citrates Nutrition 0.000 description 22
241000700159 Rattus Species 0.000 description 12
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 12
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 12
229940116269 uric acid Drugs 0.000 description 12
201000001431 Hyperuricemia Diseases 0.000 description 6
229940079593 drug Drugs 0.000 description 6
239000003814 drug Substances 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000011734 sodium Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
238000001035 drying Methods 0.000 description 3
239000001508 potassium citrate Substances 0.000 description 3
229960002635 potassium citrate Drugs 0.000 description 3
QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 3
235000011082 potassium citrates Nutrition 0.000 description 3
239000005715 Fructose Substances 0.000 description 2
229930091371 Fructose Natural products 0.000 description 2
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
230000029142 excretion Effects 0.000 description 2
238000005259 measurement Methods 0.000 description 2
238000000034 method Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
230000002485 urinary effect Effects 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000009911 Urinary Calculi Diseases 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
230000003355 alkalizing urine Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000004821 distillation Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000008187 granular material Substances 0.000 description 1
XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000000691 measurement method Methods 0.000 description 1
238000002483 medication Methods 0.000 description 1
238000000465 moulding Methods 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
229960003975 potassium Drugs 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000008085 renal dysfunction Effects 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
235000019263 trisodium citrate Nutrition 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Landscapes

Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

JP5515984A 1984-03-21 1984-03-21 尿アルカリ化剤組成物 Granted JPS60197623A (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP5515984A JPS60197623A (ja)	1984-03-21	1984-03-21	尿アルカリ化剤組成物

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP5515984A JPS60197623A (ja)	1984-03-21	1984-03-21	尿アルカリ化剤組成物

Publications (2)

Publication Number	Publication Date
JPS60197623A JPS60197623A (ja)	1985-10-07
JPH0568449B2 true JPH0568449B2 (fr)	1993-09-29

Family

ID=12990961

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP5515984A Granted JPS60197623A (ja)	1984-03-21	1984-03-21	尿アルカリ化剤組成物

Country Status (1)

Country	Link
JP (1)	JPS60197623A (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN109430667A (zh) *	2018-10-19	2019-03-08	张东祥	一种具有降尿酸作用的组合物及固体饮料

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS58194817A (ja) *	1982-05-06	1983-11-12	アルザ・コ−ポレ−シヨン	カリウム補欠療法用組成物

1984
- 1984-03-21 JP JP5515984A patent/JPS60197623A/ja active Granted

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS58194817A (ja) *	1982-05-06	1983-11-12	アルザ・コ−ポレ−シヨン	カリウム補欠療法用組成物

Also Published As

Publication number	Publication date
JPS60197623A (ja)	1985-10-07

Publication	Publication Date	Title
Iseri et al.	1975	Magnesium deficiency and cardiac disorders
JPS6064918A (ja)	1985-04-13	消炎剤注射液
JPH0429680B2 (fr)	1992-05-19
JP5204359B2 (ja)	2013-06-05	透析用剤およびその製造方法
Owen et al.	1960	Renal tubular disease with muscle paralysis and hypokalemia
KR100966977B1 (ko)	2010-06-30	항생 활성을 갖는 약제 조성물
Umeki et al.	1988	Supplemental fosfomycin and/or steroids that reduce cisplatin-induced nephrotoxicity
WO2022042450A1 (fr)	2022-03-03	Application de sel pharmaceutiquement acceptable du tris(hydroxyméthyl)aminométhane à des médicaments pour le traitement de l'hyperuricémie
US4185093A (en)	1980-01-22	Preparation and method for treatment of hypocalcemia, hypophosphatemia and downer cow syndrome in animals
EP0022429B1 (fr)	1982-12-15	Procédé de préparation d'agents de neutralisation de l'acide gastrique et les agents de neutralisation de l'acide gastrique
SU1009467A1 (ru)	1983-04-07	Средство дл растворени мочевых конкрементов
US4966774A (en)	1990-10-30	Superoxide dismutase composition
US4190655A (en)	1980-02-26	Amiloride citrate
US7662364B2 (en)	2010-02-16	Drug for hyperphospheremia and its preparative method
JPH0579648B2 (fr)	1993-11-04
JP2003339853A (ja)	2003-12-02	安定な透析用剤
JPH0568449B2 (fr)	1993-09-29
US4098883A (en)	1978-07-04	Aluminum compound and pharmaceutical compositions containing same
JPH0430373B2 (fr)	1992-05-21
JPH0430374B2 (fr)	1992-05-21
US3055805A (en)	1962-09-25	Process of treating acidosis with t.h.a.m.
JPS59110621A (ja)	1984-06-26	利尿剤
JP2720165B2 (ja)	1998-02-25	ぶどう糖電解質配合剤
US4402943A (en)	1983-09-06	Antihypertension treatment
JP2772717B2 (ja)	1998-07-09	高尿酸血症および痛風治療用の薬剤としてのアモルファス状または結晶状のオキシプリノールのアルカリ塩およびアルカリ土類塩